Qbeco ssi (DrugBank: -)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
97 | Ulcerative colitis | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02426372 (ClinicalTrials.gov) | July 2015 | 21/4/2015 | Safety and Efficacy of QBECO in Moderate to Severe Ulcerative Colitis | An Open Label, Dose Ranging, Exploratory Study to Evaluate the Safety, Tolerability, Compliance, Mechanism of Action and Efficacy of QBECO Site Specific Immunomodulation for the Induction of Clinical Response and Remission in Subjects With Moderate to Severe Ulcerative Colitis | Ulcerative Colitis | Biological: QBECO SSI | Qu Biologics Inc. | NULL | Completed | 19 Years | N/A | All | 11 | Phase 2 | Canada |